Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

SEC Filings

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • SEC Filings
    • Quarterly Results
  • Contact
  • Email Alerts
Filing date Form Description Filing Group View
03-21-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-007397.rtf
0001437749-23-007397.xls
0001437749-23-007397.pdf
View HTML
03-17-2023 DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
0001437749-23-006961.rtf
0001437749-23-006961.xls
0001437749-23-006961.pdf
View HTML
03-17-2023 DEFC14A

Definitive proxy statement in connection with contested solicitations

Proxy Filings
0001477932-23-001547.rtf
0001477932-23-001547.xls
0001477932-23-001547.pdf
View HTML
03-16-2023 PRRN14A

Non-management revised preliminary proxy soliciting materials

Proxy Filings
0001477932-23-001508.rtf
0001477932-23-001508.xls
0001477932-23-001508.pdf
View HTML
03-16-2023 DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
0001437749-23-006905.rtf
0001437749-23-006905.xls
0001437749-23-006905.pdf
View HTML
03-15-2023 DEFC14A

Definitive proxy statement in connection with contested solicitations

Proxy Filings
0001437749-23-006586.rtf
0001437749-23-006586.xls
0001437749-23-006586.pdf
View HTML
03-15-2023 DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
0001437749-23-006593.rtf
0001437749-23-006593.xls
0001437749-23-006593.pdf
View HTML
03-15-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006771.rtf
0001437749-23-006771.xls
0001437749-23-006771.pdf
View HTML
03-13-2023 8-K

Report of unscheduled material events or corporate event

Current Reports
0001437749-23-006250.rtf
0001437749-23-006250.xls
0001437749-23-006250.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-13-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006274.rtf
0001437749-23-006274.xls
0001437749-23-006274.pdf
View HTML
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top